Search

Your search keyword '"P. Gosse"' showing total 112 results
Start Over "P. Gosse" Journal journal of human hypertension
112 results on '"P. Gosse"'

4. Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study

Author

Saxena, Manish, Schmieder, Roland E., Kirtane, Ajay J., Mahfoud, Felix, Daemen, Joost, Basile, Jan, Lurz, Philipp, Gosse, Philippe, Sanghvi, Kintur, Fisher, Naomi D. L., Rump, Lars C., Pathak, Atul, Blankestijn, Peter J., Mathur, Anthony, Wang, Yale, Weber, Michael A., Sharp, Andrew S. P., Bloch, Michael J., Barman, Neil C., Claude, Lisa, Song, Yang, Azizi, Michel, and Lobo, Melvin D.

Published
2022
Full Text
View/download PDF

20. Long-term evolution of ambulatory blood pressure and cardiovascular events in hypertensive patients

Author

Gosse, Philippe, Doublet, Julien, Gaudissard, Julie, Boulestreau, Romain, and Cremer, Antoine

Abstract

Ambulatory blood pressure monitoring (ABPM) is now considered the gold standard to evaluate BP, and predicts related cardiovascular risk. However, no study has reported the association of long-term changes in ABPM with the incidence of cardiovascular events, therefore the objective of this work. We included patients from the Bordeaux cohort of hypertensive patients, who had undergone at least two ABPM; the first was performed before or after antihypertensive treatment was started, and the second was the last recording available before any cardiovascular event. We included 591 patients (mean age, 54 years) with a 7-year average interval between the first and last ABPM, a 10-year average follow-up, and a total of 111 cardiovascular events. The patients were divided into four groups: G0, first and last 24 h systolic blood pressure (SBP) < 130; G1, first 24 h SBP ≥ 130, last 24 h SBP < 130; G2, first 24 h SBP < 130, last 24 h SBP ≥ 130; and G3, first 24 h SBP ≥ 130, last 24 h SBP ≥ 130 mmHg. Baseline ABPM better predicted future events than the last ABPM. G0 and G2 had similar survival. G1 and G3 had a worse prognosis than G0 and G2, while G1 had an intermediate risk between G0 and G3, indicating some benefit of treatment. In conclusion, our study showed the prognostic value of the first ABPM recorded in hypertensive patients and the persistence of risk when 24 h BP is controlled by antihypertensive treatment.

Published
2021
Full Text
View/download PDF

21. Is headache at admission associated with higher rate of recent brain MRI injury during malignant hypertension crisis?

Author

Tillement, Jeremie, Lucas, Ludovic, Cremer, Antoine, Gosse, Philippe, Doublet, Julien, Sibon, Igor, and Boulestreau, Romain

Abstract

Reliable clinical signs associated with recent brain injuries during malignant hypertension crisis are lacking. In this single-center study we compared the prevalence of brain MRI injuries between fully asymptomatic patients and those with headache; we found no significant differences, suggesting that headache is not associated with recent brain injuries during malignant hypertension.

Published
2022
Full Text
View/download PDF

22. Does eplerenone have a future in the management of hypertension in Europe?

Author

P Gosse and R J Macfadyen

Subjects
Infarction, Pharmacology, Spironolactone, Drug Costs, chemistry.chemical_compound, Mineralocorticoid receptor, Internal Medicine, medicine, Humans, Mineralocorticoid Receptor Antagonists, Heart Failure, Clinical Trials as Topic, Aldosterone, business.industry, Antagonist, medicine.disease, United Kingdom, Eplerenone, Europe, chemistry, Medical profession, Hypertension, business, medicine.drug
Abstract

Eplerenone (Inspra, Pfizer, New York, USA), a 9,11-epoxy derivative of spironolactone, is the secondaldosterone antagonist commercially available forthe present time. In the USA, it received Food andDrug Administration approval in September 2002for the treatment of hypertension, and in July 2003for post-myocardial infarction congestive heartfailure.The medical profession has been looking forwardto this new inhibitor of aldosterone receptors asit appears to present significantly fewer adverseeffects than does spironolactone, owing to a moreselective binding to the mineralocorticoid receptor.

Published
2006

23. Malignant hypertension and interferon-beta: a case report

Author

A Lacraz, P Gosse, V Galantine, and S Rubin

Subjects
Ramipril, medicine.medical_specialty, business.industry, Renal artery stenosis, medicine.disease, Atenolol, Surgery, Irbesartan, Blood pressure, Hypertensive retinopathy, Bisoprolol, Internal medicine, Internal Medicine, medicine, Cardiology, Amlodipine, business, medicine.drug
Abstract

On 23 May 2012, a 41-year-old patient was admitted to hospital following a convulsive episode and severe hypertension. She had been treated for multiple sclerosis by interferon-beta since 2002. Her usual blood pressure (BP) values were unknown. She did not have any other cardiovascular risk factors. On admission to the emergency unit her BP was 220/140 mm Hg, and she was in a convulsive state. On initial evaluation, there was hemolysis, low serum potassium (3.2 mmol l−1), secondary hyperaldosteronism, and an elevation of cardiac, hepatic and pancreatic enzymes (Table 1). The electrocardiogram and the echocardiography were normal. There was no evidence of renal artery stenosis on Doppler echography, and adrenals, liver and pancreas were normal on computed tomography scan. Magnetic resonance imaging (MRI) of the brain showed ‘posterior regressive encephalopathy syndrome’ (PRES), and on fundal examination there was grade III hypertensive retinopathy. The patient was admitted to the intensive care unit and required intubatation and ventilation. Interferon-beta was stopped and she was given nicardipine IV to control BP, but the hemolysis persisted with worsening renal function. After extubation on 26 May she was started on bisoprolol. After the acute phase, the patient was transferred to the kidney unit on 05/06/2012. Blockers of the renin–angiotensin aldosterone system were titrated (progressive introduction of ramipril up to 10 mg per day followed by irbesartan up to 300 mg per day along with atenolol 100 mg per day). Amlodipine 10 mg was then administered reducing the BP below 140/90 mm Hg; all biologic parameters were normalized in 4 weeks (Table 1).

Published
2013
Full Text
View/download PDF

24. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression

Author

A, Cohen, B, Bregman, E, Agabiti Rosei, B, Williams, O, Dubourg, P, Clairefond, P, Brudi, P, Gosse, and P, Guéret

Subjects
Adult, Male, Adolescent, Felodipine, Biphenyl Compounds, Tetrazoles, Blood Pressure, Irbesartan, Calcium Channel Blockers, Treatment Outcome, Double-Blind Method, Echocardiography, Hypertension, Humans, Female, Hypertrophy, Left Ventricular, Antihypertensive Agents, Follow-Up Studies
Abstract

The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg. A population of 360 men and women of non-childbearing potential,18 years of age, with hypertension, newly diagnosed or after a 3-week washout from previous anti-hypertensive or vasodilator therapies, will be randomised at approximately 80-90 European sites. Add-on therapy with hydrochlorothiazide and atenolol will be allowed for blood pressure control. Patients will be studied by two-dimensional and M-mode echocardiography at baseline (central validation of LV hypertrophy), on randomisation day, and after 6 and 12 months randomised therapy. Blinded analysis of echocardiograms will be performed at a central laboratory, which will provide measurements of the LV mass index (LVMI), determined by M-mode readings according to Devereux formula and using the Penn convention. The primary end-point of the study will be the change in LVMI from baseline to 12 months. The study power is 90% to detect differences between groups from baseline of approximately 8 g/m2.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results